Patheon IncTSX: PTI

Patheon announces second quarter results

· Issued by Patheon Inc via CNW
TORONTO, June 2 /CNW/ - Patheon (TSX:PTI), a leading global provider of
drug development and manufacturing services to the international
pharmaceutical industry, announces its results for the second quarter ended
April 30, 2005.

Second Quarter Results

-   Revenues increased 50% to $184.1 million;
-   Internal revenue growth was 13%; strategic growth was $45.1 million;
-   EBITDA increased 93% to $24.3 million (13.2% of revenues) from
    $12.6 million (10.3%) a year ago;
-   Cash provided from operations increased 76% to $17.7 million;
-   Net earnings increased 22% to $3.8 million; earnings per share were
    3.4 cents versus 6.0 cents a year ago.

Year-to-Date Results

-   Revenues increased 47% to $338.0 million;
-   Internal revenue growth was 17%; strategic growth was $69.0 million;
-   EBITDA rose 95% to $45.9 million (13.6% of revenues) from
    $23.6 million (10.2%) a year ago;
-   Cash provided from operations increased 79% to $36.7 million;
-   Net earnings increased 72% to $9.8 million; earnings per share rose
    to 12.1 cents from 11.0 cents.

"We are pleased to report a strong progression in the fundamentals of our
business over the second quarter last year - consolidated revenues were up
50%, organic revenue growth was 13%, EBITDA increased 93% and cash flow from
operations grew 76%," said Mr. Robert C. Tedford, Chief Executive Officer of
Patheon Inc. "These results include the first full quarter of our MOVA
operations acquired in late December 2004 which added strategic revenue growth
of $45.1 million in the quarter. On a year-to-date basis, the MOVA operations
were accretive to earnings per share.
"We are particularly pleased to note the strong growth in cash provided
from operations, an important metric of our company's progress," said Mr.
Tedford. "Through the first half of the year, the company generated cash from
operations of $37 million, or 79% more than the same period last year."

Revenues and Margins
--------------------
The increase in consolidated revenues of $61.3 million during the quarter
included internal growth of $16.2 million and strategic growth of
$45.1 million related to the MOVA operations acquired on December 23, 2004.
Prescription (Rx) manufacturing and PDS services accounted for 84% of
consolidated revenues compared with 79% a year ago, with Rx and PDS revenues
up 66% and 32%, respectively. Over-the-counter revenues increased 13%.
Revenues from sites in North America and Europe represented 72% and 28%,
respectively, of consolidated revenues in the quarter, compared with 62% and
38% a year ago, reflecting the addition of the MOVA operations.
"As in the first quarter, internal growth was strong across all service
activities," commented Mr. Tedford. "Internal growth in Rx manufacturing
revenues was 11% in the quarter and 13% year-to-date. The global demand for
our PDS services continues to be strong with growth of 32% in the quarter and
41% year-to-date.
"MOVA revenues in the second quarter amounted to $45.1 million which, as
anticipated, were impacted by scheduled facility shutdowns," continued
Mr. Tedford. "MOVA revenues were also impacted by the shortage of a client-
supplied active pharmaceutical ingredient ("API") on a large-volume product
and an adjustment in production requirements for a new product launched in
2004," continued Mr. Tedford.
"We are pleased with our performance in Europe where revenues increased
7% in the quarter on a constant exchange rate basis," commented Mr. Tedford.
"In particular, we would like to note the improvement in the financial results
of our Swindon operations following the restructuring in 2004. The Swindon
site reported positive EBITDA in the quarter and is moving steadily toward its
objective of being EBITDA-positive for the full fiscal year."
EBITDA amounted to $24.3 million, an increase of $11.7 million or 93%
over a year ago. The EBITDA margin in the quarter was 13.2% compared with
10.3% a year earlier. The growth in EBITDA margin was largely attributable to
the MOVA operations, which have higher operating margins than those of other
operations in the Patheon network. The higher year-over-year margins were also
attributable to the growth in Rx and PDS revenues together with the
improvement in the Swindon performance, offset by the volatility of new
product launches in North America, a change in the mix of Rx and OTC products
manufactured at the Cincinnati and Whitby sites and a delay in the start-up of
new sterile capacity in Ferentino due to the regulatory approval process. MOVA
margins were lower than in the first quarter because of reduced site capacity
utilization in the second quarter.
Net earnings increased by 22% to $3.8 million in the second quarter.
However, earnings per share of 3.4 cents were lower than the 6.0 cents
achieved a year earlier because of reduced capacity utilization at the MOVA
sites as well as the impact of changes in product mix at the North American
sites.
Cash provided from operations increased 76% to $17.7 million in the
second quarter, and 79% to $36.7 million for the year to date. Cash and cash
equivalents at April 30, 2005 were $16.2 million including restricted cash at
MOVA of $4.0 million, compared with $7.6 million at the end of the 2004 fiscal
year.
At quarter end, the Company's consolidated interest bearing long term
debt to shareholders' equity was 65% compared with 62% last quarter and 56% at
year end, reflecting the increase in long-term debt related to the acquisition
of MOVA, offset by the increase in shareholders' equity related to the common
share offering in the first quarter.
The MOVA acquisition agreement provides for two earn-out arrangements
relating to MOVA's operating results for two specific periods. The maximum
amounts for the first and second earn-outs are $65 million and $26 million,
respectively. The Company has placed into escrow $87,825,000 to support
potential payments under the earn-out agreement. An agreement has been reached
with the former MOVA shareholders that the first earn-out of $65 million will
be paid in full and that the funds will be disbursed from escrow shortly. It
is currently not possible to determine the extent of the payment, if any,
under the second earn-out.

Outlook

"In the second half of 2005, we will continue to execute our strategy and
build on the progress that we have achieved in positioning Patheon as one of
the premier suppliers of pharmaceutical development and manufacturing services
in the world," said Mr. Tedford.
"Our PDS pipeline continues to show solid growth," commented Mr. Tedford.
"At quarter end, there were a total of 128 projects in our PDS business,
including seven at the NDA stage. This compares with a total of 112 projects
at the end of fiscal 2004.
"Our commercial business, particularly our Rx manufacturing, continues to
show healthy momentum driven by both internal growth and the recent
acquisition of MOVA," added Mr. Tedford. "At our MOVA operations, we expect
that the temporary situation with respect to API availability for a large-
volume product will improve through the third and fourth quarters. In the
meantime, demand for the product remains strong and MOVA has available
capacity to produce client back orders as soon as API becomes available.
"In Europe, we recently received approval from the Italian Ministry of
Health for the manufacture of large-volume parenterals at our Ferentino site,
further enhancing our service offering to the European market," commented
Mr. Tedford. "In addition, we received a positive FDA pre-approval inspection
at our Swindon, U.K. facility for a sterile non-cephalosporin product being
manufactured at the site that is destined for the U.S. and other markets. This
is an excellent achievement for our Swindon site, which already has FDA
approval for products manufactured in its cephalosporin operations. The site
is now able to manufacture both cephalosporin and non-cephalosporin products
for the world's three largest pharmaceutical markets - the U.S., Europe and
Japan."
"Looking ahead, we will continue to focus on enhancing and presenting the
value proposition of the New Patheon to the pharmaceutical industry,"
concluded Mr. Tedford. "Our goal is to maximize our full-service approach, our
value-added manufacturing capabilities and our ability to supply the world's
largest pharmaceutical markets with high-quality product, all for the benefit
of both our clients and shareholders."

This management's discussion and analysis of financial condition and
results of operations contains forward-looking statements with respect to the
Company, including its business operations and strategy and financial
performance and condition. Although management believes that the expectations
reflected in such forward-looking statements are reasonable, such statements
involve risks and uncertainties. Actual results may differ materially from
those expressed or implied by such forward-looking statements. Factors that
could cause actual results to differ materially from expectations include, but
are not limited to, currency fluctuations, the level of outsourcing services
required by the pharmaceutical companies (and in particular the Company's
clients), the impact of changes in pharmaceutical development and
manufacturing regulations and general economic and market factors (including
inflation and changes in laws) and other factors discussed in materials filed
with applicable securities regulatory authorities from time to time.

All amounts reported are in U.S. dollars unless otherwise indicated.

Patheon Inc. will host a webcast conference call with financial analysts
on its second quarter results on Friday, June 3, 2005 at 10:00 a.m. (Eastern
Standard Time). Representing Patheon on the call will be: Robert Tedford,
Chief Executive Officer; Nick DiPietro, President and Chief Operating Officer;
and Ronald Mitchell, Chief Financial Officer. Interested parties are invited
to access the call live, in listen-only mode, via telephone, at (416) 640-1907
or toll-free, at 1 800-814-4941 (Please call between five and fifteen minutes
in advance.) A live audio webcast, with a slide presentation, will be
available on www.patheon.com. An archived version of the Q2 webcast will be
available on www.patheon.com for three months.

ABOUT PATHEON

Patheon (TSX:PTI; www.patheon.com) is a leading global provider of drug
development and manufacturing services to the international pharmaceutical
industry. With the addition of its wholly owned subsidiary MOVA Pharmaceutical
Corporation, acquired in December 2004, Patheon operates a network of 14
facilities in the United States, Canada and Europe, employing more than 5,800
people and serving a client base of 180 pharmaceutical and biotechnology
companies.


<<
Consolidated Statements of Earnings
(unaudited)

                             Three months ended         Six months ended
                                       April 30,                April 30,

                                           %                         %
                          2005     2004  change     2005     2004  change
-------------------------------------------------------------------------
(in thousands of
 U.S. dollars, except
 per share amounts)          $        $                $        $
-------------------------------------------------------------------------
Revenues               184,088  122,818   49.9%  338,035  230,598   46.6%
Operating expenses     159,454  109,823   45.2%  291,259  206,518   41.0%
Stock-based
 compensation              348      382   -8.9%      843      495   70.3%
                      ------------------------- -------------------------
Earnings before
 depreciation and
 amortization,
 interest and income
 taxes                  24,286   12,613   92.5%   45,933   23,585   94.8%
                      ------------------------- -------------------------
(as a % of revenues)     13.2%    10.3%            13.6%    10.2%

Depreciation             8,858    5,779   53.3%   16,677   11,071   50.6%
Amortization of
 intangible assets
 (note 3)                3,244        -            4,524        -
Interest                 4,681    1,264  270.3%    7,014    2,407  191.4%
Amortization of
 deferred financing
 costs (note 11)         1,586        -            4,157        -
                      ------------------------- -------------------------
Earnings before
 income taxes            5,917    5,570    6.2%   13,561   10,107   34.2%
Provision for income
 taxes                   2,134    2,468  -13.5%    3,774    4,416  -14.5%
                      ------------------------- -------------------------
Net earnings for the
 period                  3,783    3,102   22.0%    9,787    5,691   72.0%
                      ------------------------- -------------------------
                      ------------------------- -------------------------
(as a % of revenues)      2.1%     2.5%             2.9%     2.5%

Earnings per share
 (note 2)
  Basic                    3.4      6.0  -43.3%     12.1     11.0   10.0%
                         cents    cents            cents    cents
                      ------------------------- -------------------------
  Diluted                  3.4      5.9  -42.4%     12.1     10.9   11.0%
                         cents    cents            cents    cents
                      ------------------------- -------------------------
Average number of
 shares outstanding
 during period:
  Basic (in thousands)  92,846   51,506   80.3%   80,710   51,506   56.7%
                      ------------------------- -------------------------
  Diluted (in
   thousands)           93,384   52,006   79.6%   81,152   52,024   56.0%
                      ------------------------- -------------------------

see accompanying notes



Consolidated Statements of Retained Earnings
(unaudited)

                                               Six months ended April 30,
                                                      2005          2004
-------------------------------------------------------------------------
(in thousands of U.S. dollars)                           $             $
-------------------------------------------------------------------------
Retained earnings, beginning of the year            76,629        65,951
Net earnings for the period                          9,787         5,691
                                              ---------------------------
Retained earnings, end of period                    86,416        71,642
                                              ---------------------------

see accompanying notes



Consolidated Balance Sheets
(unaudited)
                                                     As at         As at
                                                  April 30,   October 31,
                                                      2005          2004
-------------------------------------------------------------------------
(in thousands of U.S. dollars)                           $             $
-------------------------------------------------------------------------
Assets
Current
  Cash and cash equivalents (note 5)                16,178         7,626
  Certificate of deposit (note 5)                    5,215             -
  Accounts receivable                              136,014        95,305
  Inventories                                       75,381        58,763
  Income taxes receivable                                -         1,029
  Prepaid expenses and other                         5,171         2,768
                                              ---------------------------
Total current assets                               237,959       165,491
                                              ---------------------------
Escrow cash (note 3)                                87,825             -
Capital assets, net                                478,864       331,725
Future tax assets                                   19,599        15,800
Goodwill (note 3)                                   89,096         2,837
Intangible assets, net (note 3)                    109,750             -
Deferred pre-operating and financing costs          15,363         5,498
Investment                                           1,193         1,232
                                              ---------------------------
                                                 1,039,649       522,583
                                              ---------------------------
                                              ---------------------------

Liabilities and Shareholders' equity
Current
  Bank indebtedness                                 19,656        21,454
  Accounts payable and accrued liabilities         122,167       105,567
  Income taxes payable                                 789             -
  Current portion of long-term debt (note 10)      125,094        11,146
                                              ---------------------------
Total current liabilities                          267,706       138,167
                                              ---------------------------

Long-term debt (note 10)                           202,725       113,116
Other long-term liabilities                         22,419        21,660
Deferred revenues (note 3)                           6,758             -
Future tax liabilities                              32,869        28,242
                                              ---------------------------
Total liabilities                                  532,477       301,185
                                              ---------------------------

Shareholders' equity
  Share capital (note 4)                           400,594       118,954
  Contributed surplus                                2,216         1,373
  Retained earnings                                 86,416        76,629
  Cumulative translation adjustment                 17,946        24,442
                                              ---------------------------
Total shareholders' equity                         507,172       221,398
                                              ---------------------------
                                                 1,039,649       522,583
                                              ---------------------------
                                              ---------------------------

see accompanying notes



Consolidated Statements of Cash Flows
(unaudited)

                                Three months ended      Six months ended
                                          April 30,             April 30,

                                   2005       2004       2005       2004
-------------------------------------------------------------------------
(in thousands of U.S. dollars,
 except per share amounts)            $          $          $          $
-------------------------------------------------------------------------
Cash provided by (used in):
Operating activities
  Net earnings for the period     3,783      3,102      9,787      5,691
  Add (deduct) charges to
   operations not requiring a
   current cash payment
    Depreciation and
     amortization                13,688      5,779     25,358     11,071
    Employee future benefits         92        640        809      1,143
    Future income taxes             175        166        282      2,124
    Stock-based compensation        348        382        843        495
    Amortization of deferred
     revenues                      (381)         -       (338)         -
                               ------------------------------------------
Cash provided from operations    17,705     10,069     36,741     20,524
Net change in non-cash working
 capital balances related to
 operations                     (14,563)     1,599    (13,145)    (1,461)
                               ------------------------------------------
Cash provided by operating
 activities                       3,142     11,668     23,596     19,063
                               ------------------------------------------
Investing activities
  Acquisition of MOVA
   Pharmaceutical Corporation
   (note 3)                         636          -   (144,545)         -
  Additions to capital assets
    - sustaining                 (3,180)    (2,792)    (4,330)    (5,351)
    - project - related          (9,683)   (14,508)   (21,996)   (25,426)
  Increase in escrow cash
   related to MOVA acquisition
   (note 3)                           -          -    (87,825)         -
  Increase in deferred
   pre-operating and financing
   costs                         (1,810)         -    (11,589)         -
                               ------------------------------------------
Cash used in investing
 activities                     (14,037)   (17,300)  (270,285)   (30,777)
                               ------------------------------------------
Financing activities
  Increase (decrease) in bank
   indebtedness                  (1,392)     3,470     (1,843)     4,448
  Increase in term loans         66,872      2,430    230,911     14,270
  Repayment of long-term debt
   and other long-term
   liabilities                  (55,775)    (3,688)  (159,160)    (5,567)
  Proceeds on issue of common
   shares before costs                -          -    199,241          -
  Share issue costs                  (5)         -     (8,947)         -
                               ------------------------------------------
Cash provided by financing
 activities                       9,700      2,212    260,202     13,151
                               ------------------------------------------
Effect of exchange rate
 changes on cash and cash
 equivalents                     (1,468)       527     (4,961)       197
                               ------------------------------------------
Net increase (decrease) in
 cash and cash equivalents
 during the period               (2,663)    (2,893)     8,552      1,634
Cash and cash equivalents,
 beginning of period             18,841     13,697      7,626      9,170
                               ------------------------------------------
Cash and cash equivalents,
 end of period                   16,178     10,804     16,178     10,804
                               ------------------------------------------

see accompanying notes


                            Patheon Inc.

    Notes to Unaudited Consolidated Financial Statements for the
                   Six Months Ended April 30, 2005

  (Dollar information in tabular form is expressed in thousands of
                            U.S. dollars)


1.  Accounting policies

The accompanying consolidated financial statements have been prepared by
the Company in accordance with Canadian generally accepted accounting
principles on a basis consistent with those followed in the most recent
audited financial statements. These consolidated financial statements do
not include all the information and footnotes required by generally
accepted accounting principles for annual financial statements and
therefore should be read in conjunction with the audited consolidated
financial statements and notes included in the Company's Annual Report
for the year ended October 31, 2004.

2.  Earnings per share

The following is a reconciliation of the weighted average number of basic
and diluted shares:

                                             Three months ended April 30,
                                                      2005          2004
-------------------------------------------------------------------------
Weighted average number of common shares
 outstanding                                    92,845,688    51,505,822
Effect of dilutive stock options                   537,988       499,983
-------------------------------------------------------------------------
Weighted average number of common shares
 outstanding - diluted                          93,383,676    52,005,805
-------------------------------------------------------------------------
-------------------------------------------------------------------------


                                               Six months ended April 30,
                                                      2005          2004
-------------------------------------------------------------------------
Weighted average number of common shares
 outstanding                                    80,709,704    51,505,822
Effect of dilutive stock options                   442,631       518,217
-------------------------------------------------------------------------
Weighted average number of common shares
 outstanding - diluted                          81,152,335    52,024,039
-------------------------------------------------------------------------
-------------------------------------------------------------------------

3.  Acquisition of MOVA Pharmaceutical Corporation

On December 23, 2004, the Company completed the acquisition of MOVA
Pharmaceutical Corporation and MOVA Investments, Inc. (collectively
"MOVA"), a leading U.S. prescription pharmaceutical contract manufacturer
located in Puerto Rico, U.S.A.

The purchase price for the shares of MOVA is based on an enterprise value
for MOVA at closing of $350,000,000. The Company issued 12,684,866 common
shares to the shareholders of MOVA in satisfaction of $81,500,000 of the
purchase price. The Company assumed approximately $133,300,000 in debt
and related costs, and paid $135,200,000 in cash at closing.

The agreement also provides for two earn-out arrangements relating to
MOVA's operating results for two specific periods. The maximum amount for
the first earn-out is $65 million and the maximum amount for the second
earn-out is $26 million. The Company has placed into escrow $87,825,000
to support potential payments under the earn-out arrangement. Subsequent
to quarter end, the Company has reached agreement with the former
shareholders of MOVA that $65 million would be paid with respect to the
first earn-out. It is expected that this payment will be made in the
third quarter from the funds placed in escrow. However, at the present
time, it is not possible to determine the extent of the payment, if any,
under the second earn-out.

The acquisition has been accounted for using the purchase method and the
accompanying consolidated financial statements include the results of
operations from the date of purchase. The purchase price was allocated in
the accounts based on the estimated fair value of the assets acquired as
follows:

                                                             ------------
                                                                       $
                                                             ------------
Current assets                                                    62,183
Capital assets                                                   142,001
Other long term assets                                             1,719
Intangible assets                                                116,274
Goodwill                                                          87,944
Current liabilities                                              (32,810)
Deferred revenue                                                  (7,096)
Future tax liabilities                                            (4,041)
                                                             ------------
Net assets acquired before assumed debt                          366,174
Less: debt assumed                                              (133,333)
                                                             ------------
Net assets acquired                                              232,841
                                                             ------------
                                                             ------------

Intangible assets, which represent the value assigned to client
contracts, are being amortized on a straight-line basis over nine years.

The purchase price and related allocations for this acquisition is
preliminary. Adjustments to the purchase price and related preliminary
allocations may occur as a result of obtaining more information regarding
asset valuations, liabilities assumed, purchase price adjustments
pursuant to the purchase agreement and revisions of preliminary estimates
of fair value made at the date of purchase.

The purchase price consideration was as follows:

                                                             ------------
                                                                       $
                                                             ------------
Cash consideration                                               141,237
Transaction costs                                                  3,308
                                                             ------------
Total cash consideration                                         144,545
Value of 12,684,866 common shares issued to shareholders
 of MOVA                                                          88,296
                                                             ------------
Total consideration                                              232,841
                                                             ------------
                                                             ------------

The value of the 12,684,866 common shares was determined based on the
average market price of the Company's common shares for the two trading
days prior to the announcement of the transaction and the two trading
days following the announcement.

4.  Share capital

The following table summarizes information on share capital and related
matters at April 30, 2005:

                                               Outstanding   Exercisable
Common shares                                   92,845,688
Common share stock options                       3,889,675     3,174,988

On December 23, 2004, the Company completed a public offering of
26,000,000 common shares for gross proceeds of approximately
$181.0 million (net proceeds of $172.7 million after offering costs). The
Company also on December 23, 2004, issued 12,684,866 common shares to the
shareholders of MOVA in satisfaction of $81.5 million of the purchase
price of the acquisition.

On January 11, 2005, the underwriters of the public offering on
December 23, 2004, exercised the over-allotment option granted to
purchase an additional 2,600,000 common shares for gross proceeds of
approximately $18.3 million (net proceeds of $17.5 million after offering
costs).

5.  Cash and cash equivalents, Certificate of deposit

The Certificate of deposit of $5,215,000 and $4,016,000 of the amount
reported as cash and cash equivalents are restricted cash and are held in
support of certain debt agreements of MOVA.

6.  Segmented information

The Company is organized and managed as a single business segment, being
the provider of commercial manufacturing and pharmaceutical development
services.

North American and European operations consist of:

                                    Three months ended April 30, 2005
                               ------------------------------------------
                                 Canada        USA     Europe      Total
                                      $          $          $          $
-------------------------------------------------------------------------
Revenues
Canada                            6,262        383        660      7,305
USA                              42,947     70,420      2,435    115,802
Europe                           10,694         58     48,326     59,078
Other geographic areas            1,425        103        375      1,903
-------------------------------------------------------------------------
Total revenues                   61,328     70,964     51,796    184,088
-------------------------------------------------------------------------
Capital assets                  109,974    177,344    191,546    478,864
-------------------------------------------------------------------------
Goodwill                          2,746     86,350          -     89,096
-------------------------------------------------------------------------


                                    Three months ended April 30, 2004
                               ------------------------------------------
                                 Canada        USA     Europe      Total
                                      $          $          $          $
-------------------------------------------------------------------------
Revenues
Canada                            8,883        479        165      9,527
USA                              27,690     30,002        816     58,508
Europe                            8,310        414     44,465     53,189
Other geographic areas              779        170        645      1,594
-------------------------------------------------------------------------
Total revenues                   45,662     31,065     46,091    122,818
-------------------------------------------------------------------------
Capital assets                   97,471     29,036    161,527    288,034
-------------------------------------------------------------------------
Goodwill                          2,521          -          -      2,521
-------------------------------------------------------------------------


                                     Six months ended April 30, 2005
                               ------------------------------------------
                                 Canada        USA     Europe      Total
                                      $          $          $          $
-------------------------------------------------------------------------
Revenues
Canada                           12,445        546      1,154     14,145
USA                              85,072    121,626      4,352    211,050
Europe                           21,300        303     87,727    109,330
Other geographic areas            2,517        219        774      3,510
-------------------------------------------------------------------------
Total revenues                  121,334    122,694     94,007    338,035
-------------------------------------------------------------------------


                                     Six months ended April 30, 2004
                               ------------------------------------------
                                 Canada        USA     Europe      Total
                                      $          $          $          $
-------------------------------------------------------------------------
Revenues
Canada                           13,388        942        177     14,507
USA                              52,238     56,409      1,314    109,961
Europe                           17,355      1,273     84,849    103,477
Other geographic areas            1,402        302        949      2,653
-------------------------------------------------------------------------
Total revenues                   84,383     58,926     87,289    230,598
-------------------------------------------------------------------------

Revenue is attributed to countries based on the location of the client's
billing address and capital assets and goodwill are based in the country
in which they are located.

Revenue information by service activity is as follows:

                                      Three months ended April 30,
                               ------------------------------------------
                                   2005                  2004
                                      $                     $
-------------------------------------------------------------------------
Commercial manufacturing -
 prescription                   132,710        72%     80,172        65%
Commercial manufacturing -
 over-the-counter                29,249        16%     25,897        21%
Development services             22,129        12%     16,749        14%
-------------------------------------------------------------------------
                                184,088       100%    122,818       100%
-------------------------------------------------------------------------
-------------------------------------------------------------------------


                                       Six months ended April 30,
                               ------------------------------------------
                                   2005                  2004
                                      $                     $
-------------------------------------------------------------------------
Commercial manufacturing -
 prescription                   238,954        70%    151,419        66%
Commercial manufacturing -
 over-the-counter                55,931        17%     48,523        21%
Development services             43,150        13%     30,656        13%
-------------------------------------------------------------------------
                                338,035       100%    230,598       100%
-------------------------------------------------------------------------
-------------------------------------------------------------------------

7.  Stock-based compensation

The Company has an incentive stock option plan. Persons eligible to
participate in the plan are directors, officers, and key employees of
Patheon and its subsidiaries or any other person engaged to provide
ongoing management or consulting services to Patheon. The plan provides
that the maximum number of shares that may be issued under the plan is
7.5% of the issued and outstanding common shares of the Company at any
point in time. At April 30, 2005, the total number of common shares
listed on the Toronto Stock Exchange (the "TSX") as available for
issuance under the plan was 6,963,427, of which 3,889,675 were reserved
for options granted and outstanding under the plan. The exercise price of
common shares subject to an option is determined at the time of grant and
the price cannot be less than the weighted average market price of the
common shares of Patheon on the TSX during the two trading days
immediately preceding the grant date. Options generally expire 10 years
after the grant date and are also subject to early expiry in the event of
death, resignation, dismissal or retirement of an optionee. Options
generally vest over three years, one-third on each of the first, second
and third anniversary of the grant date.

Stock options granted prior to November 1, 2003 are accounted for using
the intrinsic value method, which does not give rise to compensation
expense. Had these stock options been accounted for at fair value, the
impact on pro-forma net earnings and earnings per share would have been:

                                 Three months ended     Six months ended
                                           April 30,            April 30,
                                   2005       2004       2005       2004
                               ------------------------------------------
                                      $          $          $          $
                               ------------------------------------------
Net earnings as reported          3,783      3,102      9,787      5,691
Pro-forma adjustments for the
 fair value of stock options
 granted prior to
 November 1, 2003                   (47)      (278)       (98)      (702)
                               ------------------------------------------
Pro-forma net earnings            3,736      2,824      9,689      4,989
                               ------------------------------------------
                               ------------------------------------------
Pro-forma earnings per share:
  Basic                             3.4        5.5       12.0        9.7
                                  cents      cents      cents      cents
  Diluted                           3.3        5.4       11.9        9.6
                                  cents      cents      cents      cents

The fair value of stock options is estimated at the date of the grant.
There were no options granted for the three months ended April 30, 2005.
The weighted average fair value of stock options granted for the six
months ended April 30, 2005 was $2.94. The weighted average fair value of
stock options granted for the comparable six-month period in 2004 was
$3.94. For the three months ended April 30, 2005, 6,668 options were
forfeited. The fair value of stock options is estimated at the date of
grant using the Black-Scholes option pricing model with the following
assumptions:

Risk free interest rate                                          3.5%
Expected volatility                                              46%
Expected weighted average life of the options                    5 years
Expected dividend yield                                          0%

8.  Other information

Cumulative translation adjustment

The cumulative translation adjustment amount will be impacted by
fluctuations in the value of the U.S. dollar relative to the Canadian
dollar, the euro and the British sterling.

Unrealized translation adjustments, which arise on the translation to
U.S. dollars of the Company's assets and liabilities, resulted in a net
unrealized currency translation loss of $5,308,000 for the three months
ended April 30, 2005 (2004 - unrealized currency translation loss of
$2,149,000). For the six months ended April 30, 2005, the unrealized
currency translation loss is $6,496,000 (2004 - unrealized currency
translation gain of $3,819,000).

The net unrealized loss in the quarter of $5,308,000 is attributable to
the strengthening of the U.S. dollar against the euro, and the Canadian
dollar as measured at April 30, 2005 and January 31, 2005, offset in part
by a weakening of the U.S. dollar against the British sterling. On a
year-to-date basis, the net unrealized loss of $6,496,000 is attributable
to the strengthening of the U.S. dollar against the Canadian dollar, as
measured at April 30, 2005 and October 31, 2004, offset in part by a
weakening of the U.S. dollar against the euro and the British sterling.

Foreign exchange

During the three months ended April 30, 2005, the foreign exchange gain
was $1,116,000 (2004 gain - $647,000). For the six months ended April 30,
2005, the foreign exchange gain was $3,377,000 (2004 gain - $1,017,000).

9.  Financial instruments

The Company utilizes financial instruments to manage the risk associated
with fluctuations in foreign exchange rates. The Company has entered into
foreign exchange expandable forward contracts with an aggregate amount of
between US$20,000,000 and US$30,000,000 as at April 30, 2005. These
contracts mature at the latest on December 31, 2005 at exchange rates
varying between 1.2360 and 1.2551 Canadian. The Company formally
documents all relationships between hedging instruments and hedged items,
as well as its risk management objective and strategy for undertaking
various hedge transactions. The mark-to-market value of these financial
instruments as at April 30, 2005 was an unrealized loss of US$398,000.

10. Long-term debt

On December 23, 2004 the Company completed a financing agreement for a
new $169,000,000 committed facility, comprising a three-year revolving
credit facility of up to $55,000,000 and a 12-month bridge facility of
$114,000,000. This bridge facility is intended to be refinanced by a term
loan within 12 months of the completion date. At the signing of the
financing agreement, $116,000,000 was drawn under these facilities in
partial payment of the cash portion of the purchase price of MOVA and
related transaction costs, and to refinance substantially all of the
Company's existing North American debt of approximately $63,000,000. At
April 30, 2005, the amount drawn under this bridge facility was reduced
to $99,700,000. Until the bridge facility is refinanced, the amount
outstanding is shown as a current liability.

Certain of the loan agreements which were assumed by the Company on
closing of the acquisition of MOVA Pharmaceutical Corporation require
MOVA to maintain certain financial covenants, as measured quarterly on a
calendar-year basis. As of December 31, 2004 and March 31, 2005, MOVA's
compliance reporting dates, MOVA was not in compliance with certain of
the financial covenants. The lending institutions have waived their
rights under the terms of the loan agreements for the non-compliance of
these covenants for a period of time up to May 1, 2006 and any
cross-default provisions of the $169,000,000 credit facility, referred to
above, have also been remedied. Therefore, no change has been made to
assumptions on long-term debt as presented in the accompanying balance
sheet.

11. Amortization of deferred financing costs

Amortization of deferred financing costs in the first six months of 2005
was $4.2 million. No amounts were recorded for the same period in the
prior year. Of the increase, $2.0 million was recorded in the first
quarter of 2005 and is of a non-recurring nature. The amortization in the
second quarter of 2005 does not include amounts of a non-recurring
nature.

12. Comparative amounts

Certain of the comparative amounts have been reclassified to conform to
the current year presentation.



                            Patheon Inc.

     Management's Discussion and Analysis of Financial Condition
                      and Results of Operations

The following is a discussion of financial condition and results of
operations of Patheon Inc. ("Patheon" or "the Company") for the three-month
and six-month periods ended April 30, 2005 and 2004 and should be read in
conjunction with the Company's consolidated financial statements and related
notes contained in this interim report. This MD&A is dated as of June 2, 2005.
The purpose of this 2005 second quarter report is to provide an update to
the information contained in the Management's Discussion and Analysis (MD&A)
section of Patheon's 2004 Annual Report, which contains a more comprehensive
discussion of Patheon's strategy, capabilities to deliver results, risks and
key performance indicators. Management assumes that the reader of this
document has access to the MD&A section of Patheon's 2004 Annual Report, the
first report for which the Company adopted the latest MD&A reporting
requirements. This document and other information can be downloaded in
portable document format (PDF) from the Company's web site at www.patheon.com
or from the SEDAR web site for Canadian regulatory filings at www.sedar.com.
To request a printed copy, the reader may also contact Patheon's transfer
agent, Computershare Trust Company of Canada, at 1-800-564-6253 or via email
at service(at)computershare.com, or Patheon at www.patheon.com.

Use of Non-GAAP Financial Measures

Except as otherwise indicated, references in this MD&A to "EBITDA" are to
earnings before depreciation and amortization, interest and income taxes. Free
cash flow is defined as cash provided by operating activities in excess of
additions to capital assets in the period. "EBITDA margin" is EBITDA divided
by revenues. EBITDA and EBITDA margin are measures of earnings or earnings
margin not recognized by generally accepted accounting principles in Canada
("Canadian GAAP"). Free cash flow is a measure of cash flows not recognized by
generally accepted accounting principles in Canada. Since each of these
measures is a non-GAAP measure that does not have a standardized meaning, it
may not be comparable to similar measures presented by other issuers.
Prospective investors are cautioned that these, and other non-GAAP measures
should not be construed as an alternative to net income determined in
accordance with Canadian GAAP as an indicator of performance or to cash flows
from operating, investing and financing activities as measures of liquidity
and cash flows. The Company has included these measures because it believes
that this information is used by certain investors to assess financial
performance.

Overview of Patheon

Patheon is focused exclusively on providing commercial manufacturing and
pharmaceutical development services to pharmaceutical companies, biotechnology
companies and specialty pharmaceutical companies located primarily in North
America, Europe and Japan. Patheon serves its international clientele from its
operating facilities in North America and Europe.
Patheon's commercial manufacturing activities relate primarily to
prescription ("Rx") and over-the-counter ("OTC") products in solid, semi-
solid and liquid dosage forms and the manufacture of Rx products in sterile
dosage forms. Conventional dosage forms include compressed tablets, hard-
shell gelatin capsules, powders, ointments, creams, gels, syrups, suspensions,
solutions and suppositories. Sterile dosage forms include aseptically filled
liquids or terminally sterilized liquids filled in ampoules, vials, bottles or
pre-filled syringes. Sterile lyophilized products are also manufactured in
both vials and ampoules.
Patheon provides manufacturing services for a broad range of products in
many dosage forms and packaging formats in accordance with client
specifications. Depending on the particular client, Patheon may be responsible
for most or all aspects of the manufacturing and packaging process, from
sourcing raw materials and packaging components to delivering the finished
product in consumer-ready form to the client. Typically, Patheon's clients
supply the active pharmaceutical ingredients ("API") used in the production
process.
The pharmaceutical development services ("PDS") provided by Patheon
include most of the pharmaceutical development services typically required by
companies conducting clinical trials and preparing for full-scale commercial
production of a new drug.
At April 30, 2005, there were a total of 128 client projects in Patheon's
PDS pipeline, including seven drug candidates at the New Drug Application
("NDA") stage.

Vision and Strategy

Patheon's vision is to be the pre-eminent provider of pharmaceutical
manufacturing and development services across several dosage forms (solid,
semi-solid, liquid, powder and sterile/injectable). To achieve its goal,
Patheon has focused on being the preferred manufacturing and pharmaceutical
development services partner to the pharmaceutical industry. The Company
intends to use its position as a comprehensive provider of commercial
manufacturing services to establish and maintain long-term relationships with
clients on a global basis.

Key Performance Drivers

In Patheon's 2004 Annual Report, several key performance drivers were
identified for the Company: (i) increasing the percentage of overall revenues
derived from higher-margin Rx commercial manufacturing and pharmaceutical
development services; (ii) improving capacity utilization at the Company's
sites, which have a largely fixed-cost base in the short term; and (iii)
mitigating the impact of changes in the foreign exchange trading relationship
between the Canadian and U.S. dollar, since the Company's contracts in North
America are primarily in U.S. dollars, but the operating expenses of its six
Canadian sites are primarily in Canadian dollars. An update on our interim
performance relating to these key measures is provided in the section below
entitled "Results of Operations".

Acquisition of MOVA in the first quarter of 2005

On December 23, 2004, the Company completed the acquisition of MOVA
Pharmaceutical Corporation and MOVA Investments, Inc. (collectively "MOVA"), a
leading U.S. prescription pharmaceutical contract manufacturer located in
Puerto Rico, U.S.A.
The purchase price for the shares of MOVA is based on an enterprise value
for MOVA at closing of $350,000,000. The Company issued 12,684,866 common
shares to the shareholders of MOVA in satisfaction of $81,500,000 of the
purchase price. The Company assumed approximately $133,300,000 in debt and
related costs, and paid $135,200,000 in cash at closing.
The agreement also provides for two earn-out arrangements relating to
MOVA's operating results for two specific periods. The maximum amount for the
first earn-out is $65 million and the maximum amount for the second earn-out
is $26 million. The Company has placed into escrow $87,825,000 to support
potential payments under the earn-out arrangement. Subsequent to quarter end,
the Company has reached agreement with the former shareholders of MOVA that
$65 million would be paid with respect to the first earn-out. It is expected
that this payment will be made in the third quarter from the funds placed in
escrow.  However, at the present time, it is not possible to determine the
extent of the payment, if any, under the second earn-out.
The acquisition has been accounted for using the purchase method and the
accompanying consolidated financial statements include the results of
operations from the date of purchase. The purchase price was allocated in the
accounts based on the estimated fair value of the assets acquired as follows:

                                                            -------------
                                                                       $
                                                            -------------
Current assets                                                    62,183
Capital assets                                                   142,001
Other long term assets                                             1,719
Intangible assets                                                116,274
Goodwill                                                          87,944
Current liabilities                                              (32,810)
Deferred revenue                                                  (7,096)
Future tax liabilities                                            (4,041)
                                                            -------------
Net assets acquired before assumed debt                          366,174
Less: debt assumed                                              (133,333)
                                                            -------------
Net assets acquired                                              232,841
                                                            -------------
                                                            -------------

Intangible assets which represent the value assigned to client contracts
are being amortized on a straight-line basis over nine years.
The purchase price and related allocations for this acquisition is
preliminary. Adjustments to the purchase price and related preliminary
allocations may occur as a result of obtaining more information regarding
asset valuations, liabilities assumed, purchase price adjustments pursuant to
the purchase agreement and revisions of preliminary estimates of fair value
made at the date of purchase.
The purchase price consideration was as follows:

                                                            -------------
                                                                       $
                                                            -------------
Cash consideration                                               141,237
Transaction costs                                                  3,308
                                                            -------------
Total cash consideration                                         144,545
Value of 12,684,866 common shares issued to shareholders
 of MOVA                                                          88,296
                                                            -------------
Total consideration                                              232,841
                                                            -------------
                                                            -------------

The value of the 12,684,866 common shares was determined based on the
average market price of the Company's common shares for the two trading days
prior to the announcement of the transaction and the two trading days
following the announcement.

Results of Operations

Three Months Ended April 30, 2005 Compared with Three Months Ended
April 30, 2004

The results for the three-month period ended April 30, 2005 include the
operations of MOVA for three months, while the results of the comparative
period do not.

Revenues by Geographic Region and Service Activity

                            Three months ended         Six months ended
                                      April 30,                April 30,
                                           %                         %
                          2005     2004  Change     2005     2004 Change
                      ---------------------------------------------------
North America
-------------
  Commercial
   Manufacturing
    Prescription        85,891   36,961    132%  154,256   69,590   122%
    Over-the-counter    28,877   25,572     13%   54,995   47,722    15%
                      ---------------------------------------------------
                       114,768   62,533     84%  209,251  117,312    78%
  Development Services  17,524   14,194     23%   34,777   25,997    34%
                      ---------------------------------------------------
                       132,292   76,727     72%  244,028  143,309    70%
                      ---------------------------------------------------
Europe
------
  Commercial
   Manufacturing
    Prescription        46,819   43,211      8%   84,698   81,829     4%
    Over-the-counter       372      325     14%      936      801    17%
                      ---------------------------------------------------
                        47,191   43,536      8%   85,634   82,630     4%
  Development Services   4,605    2,555     80%    8,373    4,659    80%
                      ---------------------------------------------------
                        51,796   46,091     12%   94,007   87,289     8%
                      ---------------------------------------------------
TOTAL
-----
  Commercial
   Manufacturing
    Prescription       132,710   80,172     66%  238,954  151,419    58%
    Over-the-counter    29,249   25,897     13%   55,931   48,523    15%
                      ---------------------------------------------------
                       161,959  106,069     53%  294,885  199,942    47%
  Development Services  22,129   16,749     32%   43,150   30,656    41%
                      ---------------------------------------------------
CONSOLIDATED REVENUES  184,088  122,818     50%  338,035  230,598    47%
                      ---------------------------------------------------
                      ---------------------------------------------------

Revenues

Consolidated revenues for the three-month period ended April 30, 2005
increased 50% or $61.3 million to $184.1 million from $122.8 million in the
same period in 2004. In the second quarter, all service activities contributed
to the growth. On a consolidated basis, commercial manufacturing revenues grew
53%, with prescription (Rx) manufacturing up 66% and over-the- counter (OTC)
manufacturing up 13% and pharmaceutical development services (PDS) revenues up
32%.
Internal growth, or new business from existing sites, was $16.2 million,
or 13%, in the second quarter of 2005, 14% in North America and 12% in Europe.
All service activities contributed to the strong internal growth in North
America. In Europe, growth was attributable principally to Rx manufacturing
and PDS services, which were up $3.6 million, or 8% and $2.0 million, or 80%,
respectively, compared with the same period in 2004. On a constant exchange
rate (CER) basis to prior year, internal growth in Europe was 7% in the second
quarter of 2005.
Prescription manufacturing and development services represented 84% of
revenues, compared with 79% for the comparable period in 2004, a result of
internal growth in Rx and PDS services and strategic growth from MOVA, where
commercial services are all Rx. OTC revenues increased 13% in the second
quarter, as compared with the same period a year ago, reflecting the continued
momentum in demand for these services at the sites in North America. PDS
revenues increased 32% in the second quarter, reflecting continuing momentum
at PDS sites in North America and Europe. PDS second quarter revenue growth
was 23% in North America and 80% in Europe, as compared with the same period a
year ago. Growth in PDS revenues reflects the continuing favourable financing
environment for drug development as well as Patheon's enhanced reputation in
the marketplace for the Company's ability to provide formulation development
services and commercialization of newly approved products for its clients.
Geographically, North American revenue growth was $55.6 million or 72%
over the same period in the prior year. Of the revenue increase, $45.1 million
was strategic growth related to the acquisition of the MOVA operations. MOVA
revenues in the second quarter were impacted by anticipated scheduled facility
shutdowns, and by the shortage of a client-supplied active pharmaceutical
ingredient ("API") on a large-volume product, and an adjustment in production
requirements for a new product launched in 2004. Net internal growth was $10.5
million, reflecting strong growth in all service activities. Growth in Rx and
OTC manufacturing services came principally from the Canadian operations, and
strong growth in PDS was experienced in the Canadian and Cincinnati sites.
Revenues from sites in North America represented 72% of total revenues in
the second quarter of 2005, compared with 62% in the same period in 2004. This
reflects the inclusion of revenues related to the MOVA operations and growth
in all service activities from the other operations in North America.
In Europe, revenues for the second quarter of 2005 were 12% higher than
the same period of 2004. European currencies remained strong against the U.S.
dollar in the second quarter of fiscal 2005 compared with the prior year. The
euro strengthened approximately 6% and the British sterling strengthened
approximately 4% against the U.S. dollar, increasing reported revenues by
approximately $2.6 million. Had European currencies remained constant to the
rates of the prior year, European revenues would have been 7% higher than the
same period in 2004, but there would have been no material impact on net
earnings or earnings per share, on a constant exchange rate (CER) basis. The
year-over-year increase in revenues is principally due to improved performance
at the UK operations.

Operating Expenses

Operating expenses comprise processing costs (principally materials,
employee and other site-related costs), marketing, sales, service, corporate
support and administrative expenses. In the second quarter of 2005, operating
expenses were $159.5 million, compared with $109.8 million in the same period
a year ago, an increase of 45%. Operating expenses as a percentage of revenues
were 86.6%, compared with 89.4% in the prior year. Excluding the impact of the
MOVA operations and the year-over-year impact of the recording of stock-based
compensation expense, operating expenses as a percentage of revenues were
comparable to the same period in the prior year.

EBITDA and EBITDA Margin

On a consolidated basis in the second quarter of 2005, EBITDA,
representing earnings before interest, income taxes, and depreciation and
amortization was $24.3 million, an increase of $11.7 million, or 93%, from the
comparable period in 2004. As a percentage of consolidated revenues, EBITDA
was 13.2% in the three-month period, compared with 10.3% in the same period a
year ago. The growth in EBITDA margin was largely attributable to the MOVA
operations, which have higher operating margins than those of other operations
in the Patheon network. The higher year-over-year margins are also
attributable to the growth in Rx and PDS revenues together with the
improvement in the Swindon performance, offset by the volatility of new
product launches in North America, a change in the mix of Rx and OTC products
manufactured at the Cincinnati and Whitby sites and a delay in the start-up of
new sterile capacity in Ferentino due to the regulatory approval process. MOVA
margins were lower than in the first quarter because of reduced site capacity
utilization in the second quarter.

Depreciation Expense

Depreciation expense was $8.9 million in the second quarter of 2005,
compared with $5.8 million in the second quarter of 2004, an increase of $3.1
million, or 53%. Of the increase, $2.5 million is attributable to additional
amounts relating to depreciation of the MOVA assets, $0.4 million is
attributable to the effect of translation to U.S. dollars of depreciation
related to Canadian and European sites, and the remainder principally related
to the capital programs at the Italian sites and capital programs in North
America, principally at the Toronto, Canada, and Cincinnati, U.S.A. sites.
Depreciation expense also includes the amortization of deferred pre- operating
costs, although there was no significant change on a year-over- year basis.

Amortization of Deferred Financing Costs

Amortization of deferred financing costs in the second quarter of 2005
was $1.6 million. No amounts were recorded for the same period in the prior
year. There were no amounts of a non-recurring nature in the second quarter.

Amortization of Intangible Assets

The amortization of intangible assets relates to the acquisition of the
MOVA operations. Intangible assets, which represent the value assigned to
client contracts, are being amortized on a straight-line basis over nine
years.

Interest Expense

Interest expense for the second quarter of 2005 was $4.7 million compared
with $1.3 million in the same period a year ago. The increase of $3.4 million,
compared with the prior year, is principally related to new debt associated
with the acquisition of the MOVA operations, increased spending in the prior
year to finance the increased capital programs in North America and Europe and
increased working capital requirements in fiscal 2004 to support new product
launches.

Earnings Before Income Taxes

Earnings before income taxes, increased 6% to $5.9 million in the second
quarter of 2005, from $5.6 million in the same period a year ago. The increase
is attributed to the inclusion of the results of the MOVA operations,
increased volumes from certain North American operations and the UK
operations, as compared with the same period in the prior year. This was
offset by increased depreciation and amortization charges in the second
quarter of 2005, related to the MOVA acquisition, and increased depreciation
and interest expense in North America and Europe, related to ongoing capital
and growth support programs.

Income Taxes

The effective income tax rate in the second quarter of 2005 was 36.1%
versus 44.3% for the same period a year ago. The lower effective tax rate
reflects the inclusion of earnings before income taxes from the MOVA
operations that are subject to the lower effective tax rate of approximately
3% under current tax legislation in Puerto Rico, U.S.A. Under current income
tax legislation in Canada, the expense of recording stock options is not
deductible for tax purposes, which increased the effective tax rate by 2.0
points in the second quarter of 2005, compared with an increase of 2.8 points
in the second quarter of 2004.

Net Earnings and Earnings Per Share

Net earnings for the second quarter of 2005 were $3.8 million, compared
with $3.1 million in the same period last year, an increase of $0.7 million,
or 22%. However, earnings per share of 3.4 cents were lower than the 6.0 cents
achieved a year earlier because of reduced capacity utilization at the MOVA
sites as well as the impact of changes in product mix at the North American
sites.
The average number of shares outstanding during the three-month period,
determined on the basic and diluted bases, increased 80%. The increase is the
result of shares issued in connection with the acquisition of MOVA, as
described in notes 3 and 4 of the financial statements herein.
Diluted earnings per share were 3.4 cents compared with 5.9 cents in the
second quarter of 2004, a decrease of 42%. Dilution arises solely from options
issued under the Company's stock option plan.

Six Months Ended April 30, 2005 Compared with Six Months Ended April 30,
2004

The results for the six-month period ended April 30, 2005 include the
operations of MOVA since the date of acquisition on December 23, 2004, while
the results of the comparative period do not.

Revenues

Consolidated revenues for the six-month period ended April 30, 2005
increased 47% or $107.4 million to $338.0 million from $230.6 million in the
same period in 2004. In the six-month period, all service activities
contributed to the growth. On a consolidated basis, commercial manufacturing
revenues grew 47%, with prescription (Rx) manufacturing up 58% and over-the-
counter (OTC) manufacturing up 15% and pharmaceutical development services
(PDS) revenues up 41%.
Internal growth, or new business from existing sites, was $38.4 million,
or 17%, in the six-month period of 2005, 22% in North America and 8% in
Europe. All service activities contributed to the strong internal growth in
North America. In Europe, growth was attributable principally to Rx
manufacturing and PDS services, which were up $2.9 million, or 4% and
$3.7 million, or 80%, respectively, compared with the same period in 2004.
Prescription manufacturing and development services represented 83% of
revenues, compared with 79% for the comparable period in 2004, a result of
internal growth in Rx and PDS services and strategic growth from MOVA, where
commercial services are all Rx. OTC revenues increased 15% in the first six
months of 2005, as compared with the same period a year ago, reflecting the
continued momentum in demand for these services at the sites in North America.
PDS revenues increased 41% in the six-month period, reflecting continuing
momentum at PDS sites in North America and Europe. PDS six-month revenue
growth was 34% in North America and 80% in Europe, as compared with the same
period a year ago. Growth in PDS revenues reflects the continuing favourable
financing environment for drug development as well as Patheon's enhanced
reputation in the marketplace for the Company's ability to provide formulation
development services and commercialization of newly approved products for its
clients.
Geographically, North American revenue growth was $100.7 million or 70%
over the same period in the prior year. Of the revenue increase, $69.0 million
was strategic growth related to the acquisition of the MOVA operations. Net
internal growth was $31.7 million, reflecting strong growth in Rx
manufacturing services, principally from the Canadian operations, and strong
growth in PDS at the Canadian and Cincinnati sites.
Revenues from sites in North America represented 72% of total revenues in
the first six months of 2005, compared with 62% in the same period in 2004.
This reflects the inclusion of revenues related to the MOVA operations and
growth in all service activities from the other operations in North America.
In Europe, revenues for the first six months of 2005 were 8% higher than
the same period of 2004. European currencies remained strong against the U.S.
dollar in the first six months of fiscal 2005 compared with the prior year.
The euro strengthened approximately 7% and the British sterling strengthened
approximately 5% against the U.S. dollar, increasing reported revenues by
approximately $5.8 million. Had European currencies remained constant to the
rates of the prior year, European revenues would have been 1% higher than the
same period in 2004. Net earnings for the first six months of 2005 would have
been higher by approximately 0.4 cents per share, on a constant exchange rate
(CER) basis.

Operating Expenses

Operating expenses comprise processing costs (principally materials,
employee and other site-related costs), marketing, sales, service, corporate
support and administrative expenses. In the first six months of 2005,
operating expenses were $291.3 million, compared with $206.5 million in the
same period a year ago, an increase of 41%. Operating expenses as a percentage
of revenues were 86.2%, compared with 89.6% in the prior year. Excluding the
impact of the MOVA operations and the year-over-year impact of the recording
of stock-based compensation expense, operating expenses as a percentage of
revenues were comparable to the same period in the prior year.

EBITDA and EBITDA Margin

On a consolidated basis in the first six months of 2005, EBITDA,
representing earnings before interest, income taxes, and depreciation and
amortization was $45.9 million, an increase of $22.3 million, or 95%, from the
comparable period in 2004. As a percentage of consolidated revenues, EBITDA
was 13.6% in the six-month period, compared with 10.2% in the same period a
year ago. The growth in EBITDA is attributed principally to the contribution
of the MOVA business and increases in PDS services in North America and
Europe.

Depreciation Expense

Depreciation expense was $16.7 million in the first six months of 2005,
compared with $11.1 million in the same period of 2004, an increase of
$5.6 million, or 51%. Of the increase, $3.6 million is attributable to
additional amounts relating to depreciation of the MOVA assets, $1.0 million
is attributable to the effect of translation to U.S. dollars of depreciation
related to Canadian and European sites, and the remainder principally related
to the capital programs at the Italian sites and capital programs in North
America, principally at the Toronto, Canada, and Cincinnati, U.S.A. sites.
Depreciation expense also includes the amortization of deferred pre- operating
costs.

Amortization of Deferred Financing Costs

Amortization of deferred financing costs in the first six months of 2005
was $4.2 million. No amounts were recorded for the same period in the prior
year. Of the increase, $2.0 million was recorded in the first quarter of 2005
and is of a non-recurring nature. The amortization in the second quarter of
2005 does not include amounts of a non-recurring nature.

Amortization of Intangible Assets

The amortization of intangible assets relates to the acquisition of the
MOVA operations. Intangible assets, which represent the value assigned to
client contracts, are being amortized on a straight-line basis over nine
years.

Interest Expense

Interest expense for the first six months of 2005 was $7.0 million
compared with $2.4 million in the same period a year ago. The increase of
$4.6 million, compared with the prior year, is principally related to new debt
associated with the acquisition of the MOVA operations and increased spending
in the prior year to finance the increased capital programs in North America
and Europe and increased spending in fiscal 2004 to support new product
launches.

Earnings Before Income Taxes

Earnings before income taxes, increased 34% to $13.6 million in the first
six months of 2005, from $10.1 million in the same period a year ago. The
increase is attributed to the inclusion of the results of the MOVA operations,
increased volumes from certain North American operations and the UK
operations, as compared with the same period in the prior year. This was
offset by increased depreciation and amortization charges, related to the MOVA
acquisition, and increased depreciation and interest expense in North America
and Europe, related to ongoing capital and growth support programs.

Income Taxes

The effective income tax rate for the six-months ended April 30, 2005 was
27.8% versus 43.7% for the same period a year ago. The lower effective tax
rate reflects the inclusion of earnings before income taxes from the MOVA
operations that are subject to the lower effective tax rate of approximately
3% under current tax legislation in Puerto Rico, U.S.A. Under current income
tax legislation in Canada, the expense of recording stock options is not
deductible for tax purposes, which increased the effective tax rate by
1.6 points in the first six months of 2005, compared with an increase of
2.0 points in the first six months of 2004.

Net Earnings and Earnings Per Share

Net earnings for the six months ended April 30, 2005 were $9.8 million,
compared with $5.7 million in the same period last year, an increase of
$4.1 million, or 72%. Basic earnings per share for the first six months of
2005 were 12.1 cents compared with 11.0 cents in the same period of 2004, an
increase of 10%. Year-to-date results were impacted by increased volumes at
MOVA and other North American sites in the first quarter, but offset somewhat
by reduced capacity utilization at the MOVA sites and changes in product mix
at the other North American sites in the second quarter. On a year-to-date
basis, the MOVA operations were accretive to earnings.
The average number of shares outstanding during the six-month period,
determined on the basic and diluted bases, increased 57% and 56% respectively.
The increase is the result of shares issued in connection with the acquisition
of MOVA, as described in notes 3 and 4 of the financial statements herein.
Diluted earnings per share were 12.1 cents compared with 10.9 cents in
the first six months of 2004, an increase of 11%. Dilution arises solely from
options issued under the Company's stock option plan.

Seasonal Variability of Results

Typically, Patheon's manufacturing and PDS revenues are lower in the
first fiscal quarter. While commercial revenues in Europe followed this
pattern, this was not the case for the European PDS revenues or for North
American PDS and commercial volumes. This is principally attributable to
higher-than-anticipated commercial volumes at the Canadian sites, related to
new business and product launches, and continuing strong demand for PDS,
related to existing contracts in the first quarter. This trend continued in
the second quarter with the inclusion of a full quarter of MOVA operations,
strong commercial demand in Europe and strong sequential demand for PDS
principally driven from the MOVA and UK operations.

Liquidity and Capital Resources

Summary of Cash flows

The following table summarizes the Company's cash flows for the periods
indicated:

                                 Three months ended     Six months ended
                                           April 30,            April 30,
                                   2005       2004       2005       2004
                               --------------------  --------------------
                                      $          $          $          $
                               --------------------  --------------------
Net earnings                      3,783      3,102      9,787      5,691
Depreciation and amortization    13,688      5,779     25,358     11,071
Future income taxes                 175        166        282      2,124
Employee future benefits             92        640        809      1,143
Stock-based compensation            348        382        843        495
Amortization of deferred
 revenues                          (381)         -       (338)         -
Working capital                 (14,563)     1,599    (13,145)    (1,461)
                               ---------  ---------  ---------  ---------
Cash provided by operating
 activities                       3,142     11,668     23,596     19,063
Cash provided by financing
 activities                       9,700      2,212    260,202     13,151
Cash used in investing
 activities                     (14,037)   (17,300)  (270,285)   (30,777)
Other                            (1,468)       527     (4,961)       197
                               ---------  ---------  ---------  ---------
Net increase (decrease) in
 cash and cash equivalents       (2,663)    (2,893)     8,552      1,634
                               ---------  ---------  ---------  ---------
                               ---------  ---------  ---------  ---------

On a year-to-date consolidated basis, the free cash flow generated in the
first quarter of 2005 was offset by higher cash needs in the second quarter to
finance working capital and capital spending programs. Free cash flow is
defined as cash provided by operating activities in excess of additions to
capital assets in the period. Free cash flow is a non-GAAP measure. Please
refer to the section describing the use of non-GAAP measures in this MD&A.
Requirements to finance working capital increased to $14.6 million in the
second quarter of 2005, compared with the generation of cash from working
capital of $1.4 million in the first quarter of 2005. This was principally a
result of the phasing of manufacturing and related client billings towards the
last half of the second quarter, as compared with the first quarter, and the
impact of the MOVA operations for the first full quarter.

Cash Provided by Operating Activities

Net earnings increased $4.1 million in the first six months of 2005,
compared with the same period in the prior year. This, combined with the
inclusion of the results of MOVA, contributed to a year-over-year increase in
cash provided by operating activities of $4.5 million, a 24% increase over the
same period in the prior year. The Company will continue its focus on working
capital management in 2005.

Cash Used in Investing Activities

Cash used in investing activities for the second quarter of 2005 was
$14.0 million, compared with $17.3 million in the same period of 2004. The
decrease is principally related to reductions in project-related capital
spending at the Toronto site and Italian sites. Cash used in investing
activities for the six months ended April 30, 2005 was $270.3 million,
compared with $30.8 million in the same period of 2004. The year-over-year
increase is principally related to the MOVA acquisition on December 23, 2004.
A summary is as follows:

                                 Three months ended     Six months ended
                                           April 30,            April 30,
                                   2005       2004       2005       2004
                               --------------------  --------------------
                                      $          $          $          $
                               --------------------  --------------------
Additions to capital assets
  Sustaining                      3,180      2,792      4,330      5,351
  Project-related                 9,683     14,508     21,996     25,426
                               ---------  ---------  ---------  ---------
Total additions to capital
 assets                          12,863     17,300     26,326     30,777
Acquisition of MOVA
 Pharmaceutical Corporation
 (note 3)                          (636)         -    144,545          -
Increase in escrow cash related
 to MOVA acquisition (note 3)         -          -     87,825          -
Increase in deferred pre-
 operating and financing costs    1,810          -     11,589          -
                               ---------  ---------  ---------  ---------
Cash used in investing
 activities                      14,037     17,300    270,285     30,777
                               ---------  ---------  ---------  ---------
                               ---------  ---------  ---------  ---------

Cash Provided by Financing Activities

The principal financing activity for the six months ended April 30, 2005
occurred in the first quarter of 2005, and was the completion of the common
share offering. Proceeds from the offering were $199.2 million, before costs,
and $190.3 million after costs. Proceeds were used to finance a portion of the
purchase price of MOVA of $350.0 million and to finance, in escrow,
approximately 90% of the maximum amount of $91.0 million potentially payable
under the earn-out agreements.

A summary is as follows:

                                 Three months ended     Six months ended
                                           April 30,            April 30,
                                   2005       2004       2005       2004
                               --------------------  --------------------
                                      $          $          $          $
                               --------------------  --------------------
Increase (decrease) in bank
 indebtedness                    (1,392)     3,470     (1,843)     4,448
Increase in term loans           66,872      2,430    230,911     14,270
Repayment of long-term debt and
 other long-term liabilities    (55,775)    (3,688)  (159,160) (5,567)
Proceeds on issue of common
 shares before costs                  -          -    199,241          -
Share issue costs                    (5)         -     (8,947)         -
                               ---------  ---------  ---------  ---------
Cash provided by financing
 activities                       9,700      2,212    260,202     13,151
                               ---------  ---------  ---------  ---------
                               ---------  ---------  ---------  ---------

Financing Arrangements and Ratios

At April 30, 2005, the Company's consolidated ratio of interest-bearing
long-term debt (including current portion) to shareholders' equity was 64.6%
compared with 62.5% at January 31, 2005 and 56.1% at October 31, 2004. At
April 30, 2005, the Company's consolidated ratio of interest-bearing debt
(including current portion and bank indebtedness) to shareholders' equity was
68.5%, compared with 66.7% at January 31, 2005 and 65.9% at the end of the
2004 fiscal year.
The Certificate of deposit of $5,215,000 and $4,016,000 of the amount
reported as cash and cash equivalents are restricted cash and are held in
support of certain debt agreements of MOVA.
Certain of the loan agreements which were assumed by the Company on
closing of the acquisition of MOVA Pharmaceutical Corporation require MOVA to
maintain certain financial covenants, as measured quarterly on a calendar-
year basis. As of December 31, 2004 and March 31, 2005, MOVA's compliance
reporting dates, MOVA was not in compliance with certain of the financial
covenants. The lending institutions have waived their rights under the terms
of the loan agreements for the non-compliance of these covenants for a period
of time up to May 1, 2006 and any cross-default provisions of the $169,000,000
credit facility, referred to above, have also been remedied. Therefore, no
change has been made to assumptions on long-term debt as presented in the
accompanying balance sheet.
On December 23, 2004 the Company completed a financing agreement for a
new $169,000,000 committed facility, comprising a three-year revolving credit
facility of up to $55,000,000 and a 12-month bridge facility of $114,000,000.
This bridge facility is intended to be refinanced by a term loan within 12
months of the completion date. At the signing of the financing agreement,
$116,000,000 was drawn under these facilities in partial payment of the cash
portion of the purchase price of MOVA and related transaction costs, and to
refinance substantially all of the Company's existing North American debt of
approximately $63,000,000. At April 30, 2005, the amount drawn under this
bridge facility was reduced to $99,700,000. Until the bridge facility is
refinanced, the amount outstanding is shown as a current liability.
With the acquisition of MOVA, the Company assumed $133.3 million of debt
in the form of bank debt and capital lease obligations secured by the assets
of MOVA.

Adequacy of Financial Resources

The Company believes that its financial resources are sufficient to fund
projected capital expenditures and debt service requirements in the normal
course of business. The Company is in the process of refinancing the bridge
facility of $99.7 million, referred to above, to a term loan facility.

Critical Accounting Policies and Estimates

General

Patheon's significant accounting policies are described in Note 1 to the
2004 consolidated financial statements. The most critical of these policies
are those related to revenue recognition, goodwill, income taxes and employee
future benefits (Notes 1, 12 and 13 of the 2004 audited financial statements).
The preparation of the consolidated financial statements requires
management to make estimates and assumptions that affect the reported amounts
of assets, liabilities, revenues and expenses. These estimates and assumptions
are based upon management's historical experience and are believed by
management to be reasonable under the circumstances. Such estimates and
assumptions are evaluated on an ongoing basis and form the basis for making
judgments about the carrying values of assets and liabilities that are not
readily apparent from other sources. Actual results could differ significantly
from these estimates.
The Company's Critical Accounting Policies have been reviewed and
discussed with the Company's Audit Committee.

Revenue Recognition

The Company recognizes revenue for its commercial manufacturing and
pharmaceutical development services when services are completed in accordance
with specific agreements with its clients and all costs connected with
providing these services have been incurred, price is fixed or determinable
and collectibility is reasonably assured.
The Company does not receive any fees on signing of contracts. In the
case of pharmaceutical development services, revenue is recognized on the
achievement of specific milestones. In the case of commercial manufacturing
services, revenue is recognized when services are complete and the product has
met rigourous quality assurance testing.

Valuation of Goodwill

The Company evaluates goodwill for impairment at least annually. If the
carrying value of the reporting unit exceeds the reporting unit's fair value,
any excess represents an impairment loss.
The goodwill shown on the financial statements for the period ended April
30, 2005 was $89.1 million and relates to the acquisition in 2000 of the
remaining shares of Global Pharm Inc., which now operates as Toronto York
Mills Operations, and from the acquisition of MOVA Pharmaceutical Corporation
on December 23, 2004. As at April 30, 2005, goodwill shown on the financial
statements relating to MOVA operations was $86.4 million and goodwill shown
relating to Toronto York Mills operations was $2.7 million.

Income Taxes

In accordance with Canadian GAAP, the Company uses the liability method
of accounting for future income taxes and provides for future income taxes for
significant temporary timing differences.
Preparation of the consolidated financial statements requires an estimate
of income taxes in each of the jurisdictions in which the Company operates.
The process involves an estimate of the Company's current tax exposure and an
assessment of temporary differences resulting from differing treatment of
items such as depreciation and amortization for tax and accounting purposes.
These differences result in future tax assets and liabilities and are
reflected in the consolidated balance sheet.
Future tax assets of $19.6 million have been recorded at April 30, 2005.
This is comprised primarily of accounting provisions related to pension and
post-retirement benefits not currently deductible for tax purposes, the tax
benefit of net operating loss carryforwards related to the UK operations and
share issue costs associated with the offering in relation to the acquisition
of the MOVA. The Company evaluates quarterly the ability to realize its future
tax assets. The factors used to assess the likelihood of realization are the
Company's forecast of future taxable income and available tax planning
strategies that could be implemented to realize the future tax assets. The
Company has available to it tax planning strategies to realize future tax
assets in order to avoid the potential loss of benefits.
Future tax liabilities of $32.9 million have been recorded at April 30,
2005. This liability is comprised primarily of tax depreciation in excess of
book depreciation.
The Company's tax filings are subject to audit by taxation authorities.
Although management believes that it has adequately provided for income taxes
based on the information available, the outcome of audits cannot be known with
certainty and the potential impact on the financial statements is not
determinable.

Employee Future Benefits

The Company provides pensions and post-retirement benefits, including
medical benefits and dental care. The determination of the obligation and
expense for defined benefit pensions and post-retirement benefits is dependent
on the selection of certain assumptions used by actuaries in calculating such
amounts. Those assumptions are disclosed in Note 13 to the Company's 2004
audited consolidated financial statements.

Risk Management

The following are updates to certain of the risks and uncertainties
described in the Management's Discussion and Analysis (MD&A) section of
Patheon's 2004 Annual Report, available on SEDAR (www.sedar.com) or on
Patheon's web site (www.patheon.com).

Foreign Currency

The Company's business activities are conducted in several currencies -
Canadian dollars and U.S. dollars for the Canadian operations, U.S. dollars
for the U.S. operations and euros and British sterling for the European
operations.
Since the European and U.S. operations conduct business principally in
their respective local currencies, the exposure to foreign currency gains and
losses is not significant. However, the Company's Canadian operations
negotiate sales contracts for payment in both U.S. and Canadian dollars, and
materials and equipment are purchased in both U.S. and Canadian dollars. The
majority of its non-material costs (including payroll, facilities' costs and
costs of locally sourced supplies and inventory) are denominated in Canadian
dollars. Approximately 65% to 75% of revenues of the Canadian operations and
approximately 15% to 25% of its operating expenses are transacted in U.S.
dollars. As a result, the Company may experience trading and translation gains
or losses because of volatility in the exchange rate between the Canadian and
U.S. dollar.
To mitigate this risk, the Company maintains net monetary asset and/or
liability balances in foreign currencies and engages in foreign currency
hedging activities using derivative financial instruments. The Company does
not purchase any derivative instruments for speculative purposes.
The Company has entered into forward exchange contracts to sell U.S
dollars and purchase Canadian dollars. The mark-to-market value of these
financial instruments as at April 30, 2005 was an unrealized loss of
$0.4 million.
Translation gains and losses related to the carrying value of the
Company's foreign operations are deferred and included in the cumulative
translation account in shareholders' equity. At April 30, 2005, the balance in
the account was a $17.9 million gain compared with a $24.4 million gain at the
end of 2004.

Additional Information

Share Capital

As of June 2, 2005, the Company had outstanding 92,845,688 common shares
and 1,029 Class I preferred shares.

Public Securities Filings

Other information about the Company, including the annual information
form and other disclosure documents, reports, statements or other information
that is filed with Canadian securities regulatory authorities can be accessed
through SEDAR at www.sedar.com.

Outlook
In the second half of 2005, the Company will continue to execute its
strategy and build on the progress that it has achieved in positioning Patheon
as one of the premier suppliers of pharmaceutical development and
manufacturing services in the world.
The Company's PDS pipeline continues to show solid growth. At quarter
end, there were a total of 128 projects in our PDS business, including seven
at the NDA stage. This compares with a total of 112 projects at the end of
fiscal 2004.
The commercial business, particularly Rx manufacturing, continues to show
healthy momentum driven by both internal growth and the recent acquisition of
MOVA. At the MOVA operations, the Company expects that the temporary situation
with respect to API availability for a large-volume product will improve
through the third and fourth quarters. In the meantime, demand for the product
remains strong and MOVA has available capacity to produce client back orders
as soon as API becomes available.
In Europe, the Company recently received approval from the Italian
Ministry of Health for the manufacture of large-volume parenterals at its
Ferentino site, further enhancing its service offering to the European market.
In addition, the Company received a positive FDA pre-approval inspection at
its Swindon, U.K. facility for a sterile non-cephalosporin product being
manufactured at the site that is destined for the U.S. and other markets. This
is an excellent achievement for the Swindon site, which already has FDA
approval for products manufactured in its cephalosporin operations. The site
is now able to manufacture both cephalosporin and non-cephalosporin products
for the world's three largest pharmaceutical markets -- the U.S., Europe and
Japan.
Looking ahead, the Company will continue to focus on enhancing and
presenting the value proposition of the New Patheon to the pharmaceutical
industry. The Company's goal is to maximize its full-service approach, its
value-added manufacturing capabilities and its ability to supply the world's
largest pharmaceutical markets with high-quality product, all for the benefit
of both its clients and shareholders.


No Auditor Review

Under National Instrument 51-102, Part 4, subsection 4.3 (3) (a), if an
auditor has not performed a review of the interim financial statements, they
must be accompanied by a notice indicating that the financial statements have
not been reviewed by an auditor.
The accompanying unaudited interim financial statements of the Company
have been prepared by and are the responsibility of management. The Company's
independent auditor has not performed a review of the financial statements for
the three-month and six-month periods ended April 30, 2005 or for the
comparative periods ended April 30, 2004.

Forward-looking Information

This management's discussion and analysis of financial condition and
results of operations contains forward-looking statements with respect to the
Company, including its business operations and strategy and financial
performance and condition. Although management believes that the expectations
reflected in such forward-looking statements are reasonable, such statements
involve risks and uncertainties. Actual results may differ materially from
those expressed or implied by such forward-looking statements. Factors that
could cause actual results to differ materially from expectations include, but
are not limited to, currency fluctuations, the level of outsourcing services
required by the pharmaceutical companies (and in particular the Company's
clients), the impact of changes in pharmaceutical development and
manufacturing regulations and general economic and market factors (including
inflation and changes in laws) and other factors discussed in materials filed
with applicable securities regulatory authorities from time to time.
>>

Patheon Inc on 6ix

Later from Patheon

All Patheon news releases